Asymchem Laboratories (Tianjin) Future Growth
Future criteria checks 1/6
Asymchem Laboratories (Tianjin) is forecast to grow earnings and revenue by 4.3% and 11.5% per annum respectively. EPS is expected to grow by 3.8% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
4.3%
Earnings growth rate
3.8%
EPS growth rate
| Pharmaceuticals earnings growth | 17.8% |
| Revenue growth rate | 11.5% |
| Future return on equity | 9.5% |
| Analyst coverage | Good |
| Last updated | 19 Aug 2024 |
Recent future growth updates
Recent updates
Is There An Opportunity With Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) 49% Undervaluation?
Jul 16
Asymchem Laboratories (Tianjin) (SZSE:002821) Is Paying Out A Dividend Of CN¥1.80
Jun 27Benign Growth For Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Underpins Its Share Price
Jun 26Does Asymchem Laboratories (Tianjin) (SZSE:002821) Have A Healthy Balance Sheet?
May 22Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Just Missed Earnings: Here's What Analysts Think Will Happen Next
Apr 03Downgrade: Here's How Analysts See Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821) Performing In The Near Term
Apr 02A Look At The Fair Value Of Asymchem Laboratories (Tianjin) Co., Ltd. (SZSE:002821)
Mar 26Asymchem Laboratories (Tianjin) Co., Ltd.'s (SZSE:002821) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 9,323 | 1,985 | 1,052 | 2,228 | 15 |
| 12/31/2025 | 7,584 | 1,639 | 862 | 1,599 | 17 |
| 12/31/2024 | 6,305 | 1,268 | 672 | 1,590 | 17 |
| 3/31/2024 | 6,976 | 1,920 | 1,481 | 2,737 | N/A |
| 12/31/2023 | 7,825 | 2,269 | 2,308 | 3,550 | N/A |
| 9/30/2023 | 8,804 | 2,791 | 1,958 | 3,312 | N/A |
| 6/30/2023 | 9,839 | 3,248 | 3,244 | 4,908 | N/A |
| 3/31/2023 | 10,445 | 3,433 | 2,543 | 4,386 | N/A |
| 1/1/2023 | 10,255 | 3,302 | 1,136 | 3,287 | N/A |
| 9/30/2022 | 9,508 | 3,094 | 452 | 2,606 | N/A |
| 6/30/2022 | 7,918 | 2,382 | -1,834 | 267 | N/A |
| 3/31/2022 | 5,915 | 1,413 | -1,832 | 217 | N/A |
| 12/31/2021 | 4,632 | 1,068 | -1,547 | 113 | N/A |
| 9/30/2021 | 3,977 | 908 | -986 | 572 | N/A |
| 6/30/2021 | 3,626 | 830 | -391 | 916 | N/A |
| 3/31/2021 | 3,438 | 766 | -514 | 624 | N/A |
| 12/31/2020 | 3,137 | 719 | -442 | 573 | N/A |
| 9/30/2020 | 2,800 | 694 | -72 | 596 | N/A |
| 6/30/2020 | 2,633 | 640 | 51 | 582 | N/A |
| 3/31/2020 | 2,459 | 570 | 92 | 574 | N/A |
| 12/31/2019 | 2,460 | 554 | 90 | 601 | N/A |
| 9/30/2019 | 2,372 | 534 | -61 | 493 | N/A |
| 6/30/2019 | 2,170 | 501 | -236 | 309 | N/A |
| 3/31/2019 | 1,948 | 457 | -222 | 351 | N/A |
| 12/31/2018 | 1,835 | 428 | -128 | 415 | N/A |
| 9/30/2018 | 1,732 | 401 | -287 | 223 | N/A |
| 6/30/2018 | 1,629 | 373 | -161 | 306 | N/A |
| 3/31/2018 | 1,497 | 356 | -184 | 181 | N/A |
| 12/31/2017 | 1,423 | 341 | N/A | 196 | N/A |
| 9/30/2017 | 1,213 | 265 | N/A | 277 | N/A |
| 6/30/2017 | 1,184 | 289 | N/A | 338 | N/A |
| 3/31/2017 | 1,207 | 269 | N/A | 372 | N/A |
| 12/31/2016 | 1,103 | 253 | N/A | 278 | N/A |
| 9/30/2016 | 1,097 | 260 | N/A | 285 | N/A |
| 12/31/2015 | 831 | 154 | N/A | 257 | N/A |
| 12/31/2014 | 716 | 102 | N/A | 127 | N/A |
| 12/31/2013 | 543 | 75 | N/A | 106 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002821's forecast earnings growth (4.3% per year) is above the savings rate (2.9%).
Earnings vs Market: 002821's earnings (4.3% per year) are forecast to grow slower than the CN market (21.8% per year).
High Growth Earnings: 002821's earnings are forecast to grow, but not significantly.
Revenue vs Market: 002821's revenue (11.5% per year) is forecast to grow slower than the CN market (13.4% per year).
High Growth Revenue: 002821's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002821's Return on Equity is forecast to be low in 3 years time (9.5%).